Compare PNNT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNNT | IMUX |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 209.2M |
| IPO Year | 2007 | 2013 |
| Metric | PNNT | IMUX |
|---|---|---|
| Price | $3.79 | $16.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.75 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 609.3K | 138.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 20.87% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.19 | $0.51 |
| 52 Week High | $7.29 | $16.60 |
| Indicator | PNNT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 71.10 | 64.08 |
| Support Level | $3.27 | $0.74 |
| Resistance Level | $3.92 | N/A |
| Average True Range (ATR) | 0.11 | 1.05 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 100.00 | 82.70 |
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.